echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Allergy: new immunotherapy to treat allergic reactions in cats

    Allergy: new immunotherapy to treat allergic reactions in cats

    • Last Update: 2021-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cat allergy is an increasingly common phenomenon characterized by hypersensitive reactions and over-immune responses to certain cat-related allergens, in particular Fel d1, a protein commonly found in its saliva, glands, skin and fur.
    allergies can be fatal from mild symptoms to the development of serious conditions such as rhinitis and asthma.
    drug therapy is an option in milder forms, only allergen-specific immunotherapy (AIT) can ensure effective and long-lasting treatment in late-stage patients.
    AIT usually includes a gradual increase in the number of associated allergens injected subsurface until a critical dose inducing long-term immune tolerance is reached.
    this, improvements in efficacy and safety are needed.
    researchers speculate that the most effective AIT can increase immune tolerance to this allergen by optimizing the immune adulation's response to Immune system T and B cells to induce the production of antibodies against Fel d 1 while keeping the inflammatory response to a minimum.
    "We're trying to explore new ways to increase AIT anti-inflammatory activity with CpG, a known immunomodulator, but at a higher safe dose than previously used for this type of therapy," explains allergy and immunologist Dr. Cathy Léonard.
    To study the cytological and clinical effects of AIT based on injection of Fel d 1 allergens combined with high-dose CpG admissors, the team attacked mice with or without Fel d 1 allergens.
    scientists observed that allergic mice treated with AIT showed significantly improved lung function compared to untreated allergic mice, with significantly reduced signs of respiratory inflammation and high reactiveness.
    Indeed, when studying Fel d 1 specific antibodies, the team noted that perverted mice treated with AIT showed lower IgE levels (usually associated with perverted reactions) and higher levels of IGA and IgG (anti-inflammatory) properties.
    addition, allergic mice treated with AIT showed a decrease in molecular levels of certain allergic cytokines produced by type 2 auxiliary T cells (Th2) compared to untreated allergic animals.
    the researchers also noted that shortly after the injection of AIT, there were a large number of immune cell types involved in allergic regulation and tolerance in the tissues of mice treated with AIT, i.e. plasma cell-like dextive cells (pDC), natural killer cells (NKs), regulatory T cells (T-regs) and regulatory B cells (B-regs).
    found that these cells express higher levels of tumor necrotic factor α (TNF-α) subjectivity 2 (TNFR-2), while NK cells also produce TNF-α cytokines, which are known to suppress allergen-specific immune responses that make these regulatory cells "brake" on the immune system.
    later, we observed a significant increase in TNF-α lungs.
    interestingly, AIT also triggered the emergence of a new and unique Treg, called bitreg, which better balances allergic and inflammatory reactions to antigens.
    , " added Dr. Léonard.
    , these findings point to strong anti-inflammatory and anti-allergic effects induced by high and safe doses of CpG adulation AIT.
    , however, it is striking that the mechanism by which this perverted reaction protects the vaccine depends on whether the vaccine has been vaccinated, and that the vaccine has never been exposed to the Fel d 1 antigen before, so it does not present a Fel d 1 antigen.
    an existing allergy state, or under established allergic conditions, such as AIT.
    of these alternatives opens up new insights into the future design of preventive and curable allergy vaccines using CpG adsage.
    (Bio Valley Bioon.com) Source: Novel immunotherapy approach to treat cat allergy Original source: Cathy Leonard et al, Comprehensive mapping of immune tolerances a regulatory TNF receptor 2 signature in murine model of successful Fel d 1-specific immunotherapy using high-dose CpG adjuvant, Allergy (2020). DOI: 10.1111/all.14716
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.